Clin2
NCT07054346Possibly a fitRecruiting

Radioactive drugs before prostate surgery for high-risk prostate cancer

Prostate CancerProstate Cancer (Diagnosis)High-risk Prostate CancerLocalized Prostate CarcinomaVery High Risk Prostate Carcinoma

Treatments studied

Part of Cancer, Kidney & urinary clinical trials.

This trial compares two radioactive drugs (177Lu-PSMA-617 and 225Ac-PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that has not spread far. The goal is to see which drug is better at shrinking the tumor and reducing the chance of cancer coming back.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
45 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You must have biopsy-confirmed prostate adenocarcinoma.
  • You must have at least one high-risk feature: Gleason score 4+4 or higher, or 4+3 with large cribriform pattern, pelvic lymph node spread seen on PSMA PET, or cancer extending outside the prostate on MRI or PSMA PET.
  • You must have no distant metastases (cancer spread to organs like bones or lungs) – only pelvic lymph node spread is allowed.
  • If you are in a treatment group, the main prostate tumor must have a high PSMA signal (SUVmax > 10) on PSMA PET, and the tumor must be larger than 1 cm on MRI.
  • You must be a candidate for and willing to undergo prostate removal surgery (prostatectomy), with or without lymph node dissection.
  • Your blood counts and organ function must be adequate: platelets ≥ 100,000, hemoglobin ≥ 10 g/dL, neutrophils ≥ 1,500, creatinine clearance (GFR) ≥ 60 mL/min, albumin ≥ 2.5 g/dL, liver enzymes ≤ 3 times upper normal limit, and bilirubin ≤ 2 times upper normal limit (or ≤ 3 times if you have Gilbert's syndrome).
  • You must agree to follow radiation safety precautions, avoid pregnancy, and not father a child during treatment and for at least 14 weeks after.
  • You must not have other active cancers (unless treated and disease-free for over 3 years, or non-melanoma skin cancer or superficial bladder cancer).
  • You must not have serious medical conditions that could interfere, such as uncontrolled heart failure, congenital long QT syndrome, uncontrolled infection, or active hepatitis B or C.
  • You must not have had prior prostate cancer therapy, except that 5-alpha reductase inhibitors (like finasteride) are allowed if stopped at least 3 weeks before starting treatment.
  • You must not have had prior external beam radiation to the prostate.
  • You must not have severe dry mouth affecting eating.
  • If you will receive the therapy through a vein (intraarterial), you must not have a severe allergy to iodinated contrast or severe atherosclerosis, and if you smoke, you must have had a prior imaging test.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06066437Recruiting· Phase 1/Phase 2
Lutetium before prostate surgery for high-risk cancer

This trial tests a radioactive drug (lutetium) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if it can shrink the tumor and improve outcomes.

Houston, Texas
NCT06259123Recruiting· Phase 2
PSMA Radiotherapy Before Prostate Cancer Surgery

This trial tests a radioactive drug (PSMA-RLT) given before surgery for prostate cancer that has spread to a few spots. It aims to see if this treatment can stop the cancer from growing further.

Vienna
NCT06546527Not yet recruiting· Early Phase 1
Study of a radioligand therapy for advanced prostate cancer

This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.

NCT07381582Not yet recruiting· Early Phase 1
Radioactive drug for advanced prostate cancer

This trial tests an experimental radioactive drug that targets a protein called PSMA found on prostate cancer cells. It aims to see if this drug is safe and can shrink tumors in men with advanced prostate cancer that has not responded to hormone therapy or chemotherapy.

Beijing, Beijing Municipality
NCT07677566Not yet recruiting· Phase 4
Combination therapy for high-risk prostate cancer before surgery

This trial tests a combination of a targeted radioactive drug (177Lu-PSMA-617) and a hormone blocker (Darolutamide) given before surgery for high-risk prostate cancer that hasn't spread. The goal is to see if this approach can improve outcomes.

Nanjing, Jiangsu
NCT07208240Recruiting· Phase 1/Phase 2
PSMA-targeted radiation before prostate removal for advanced cancer

This trial tests giving a radioactive drug (PSMA-targeted) before surgery for prostate cancer that has spread locally but not to other parts of the body. The goal is to see if it helps lower the risk of the cancer coming back.

Petah Tikva

Hear when a new Prostate cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.